InVitro International (IVRO)

[adijas]

Nice! I'm willing to wait here. No doubt this will move some day.

[Lazarus]

patience...

I held SPND for around 6-8 years before it began to move from the .40 range. Then within a few years it hit ~ 10 bucks. (my highest sell price ~ $6.00 bucks)

[adijas]

Yeah, lack of interest is weird. Hope one day IVRO will be a micro cap.

[Lazarus]

The quintessential nano-cap.

[adijas]

Filings out. Some interesting info in it.

Cash $ 421.000, assets 1.3 million, liabilities just $ 49,170

Net profit last Q $.002 per share


The CORROSITEX™ assay has been marketed since 1991 and the IRRITECTION® assays have been marketed since 1989. All three test methods are currently marketed by Company internal personnel through industry contacts, standard advertising and a strategic alliance with INT.E.G.RA, a division of Italy based Res Pharma, which sells and distributes the Company’s test kits and laboratory testing services in Italy and 21 other countries around the world. The Company is also in the process of developing a targeted social media marketing program.


As a result of the OECD Expert Committee meeting in November 2017, the Company’s Ocular IRRITECTION® test method has now moved on to the next phase of the OECD adoption process for acceptance as a substitute for animal testing on all future cosmetic products.

https://backend.otcmarkets.com/otcapi/company/financial-report/193130/content

https://backend.otcmarkets.com/otcapi/company/financial-report/193126/content

[Lazarus]

From the blog on their website>>>>

THIS

[Lazarus]

Anybody notice THIS?

Rolf Kleiner looks like an interesting addition

[Lazarus]

IVRO seeing some selling today. I would guess its the penny players who jumped on for the momo, bought over 4 cents, and want to move on. One of my sons told me he was filled for 15k at .032

With book value of .044 and years of profitability selling at below 4 cents make little sense to me.

[unknownotc]

Article on IVRO

https://unknownotc.wordpress.com/2017/12/15/invitro-international-ivro/

[adijas]

Filings out https://www.otcmarkets.com/stock/IVRO/filings

[adijas]

Also on OTC markets

INVITRO’S OCULAR IRRITECTION® REACHES FINAL STAGE OF OECD’S TEST METHOD ADOPTION Placentia, CA - November 15, 2017 Last week, at the annual meeting of the Organization for Economic Common Development (OECD) Expert Group on Skin and Eye Irritation Test Methods in Paris, InVitro International and its long-time Italian in vitro testing partner, INT.E.G.RA, received final OECD Expert Group on Skin and Eye Irritation Test Methods acceptance of Ocular Irritection®. The OECD is generally viewed as the world’s foremost regulatory authority on in vitro test methods. The company plans to move forward immediately to compose a Test Guideline (TG) document for submission to the OECD. The TG will make our test method both clear and available to all laboratories that wish to use the Ocular Irritection® test. Completion of a TG can take several months to more than one year. InVitro CEO & President, W. Richard Ulmer, said: “This nearly global level of regulatory support for a non-mammalian (plant protein) test technology not only means much to InVitro, but also could possibly encourage more innovative in vitro testmethods to be developed as well. We continue to be very enthusiastic about the future for non-animal testing on a global basis. Ocular Irritection® is the only such method with OECD acceptance which can be shipped anywhere in the world with significant remaining shelf life for its laboratory users.” This release may contain "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied by forward looking statements. These risks and uncertainties include, but are not limited to: acceptance of the Company’s technology by customers or regulatory agencies, changes in market conditions and other competitive factors. The forward-looking statements are made as of the date of this press release and the Company assumes no obligation to update such statements.

[db7]

pr on website:

http://invitrointl.com/invitros-ocular-irritection-reaches-final-stage-of-oecds-test-method-adoption/

[adijas]

Very nice and informative website.

[db7]

regarding competition:

"



Who Are Your Competitors With Regard To Your Core Product Line?



Posted by inadmin on July 24, 2017


Although there are probably less than a handful of competitors in the field of in vitro (non-animal) irritancy/toxicity testing (Advanced Tissue Sciences ‘ATS’ – manufacturer of Skin2 – recently discontinued the manufacture and sale of its product), all of them are living cell-based systems. This means that, in comparison to InVitro’s technology, they are more expensive, the shelf life is much shorter and the results correlate no better. Quite frankly, our biggest competitors are prospect companies which do not test AT ALL. We also know that there are companies out there using pH to determine corrosive levels of their hazardous materials in an effort to comply* with Department of Transportation regulations. Yes, a box of pH strips is very inexpensive and the cost to have an outside laboratory run a pH test is also less expensive than a Corrositex test; however, these companies are not aware that pH oftentimes overclassifies materials, thus significantly increasing costs for cumulative packing, shipping and insurance. In these instances, InVitro International has saved businesses who will listen lots of money.

*pH testing is NOT approved by the Department of Transportation(DOT) for the classification of corrosive levels of hazardous materials — as you know, Corrositex is approved by the DOT for this purpose.



"

[db7]

ask jumped over .09 too, maybe cheap shares are gone here(?)

[adijas]

New website, Kleiner assistance... things are coming together.

[db7]

Had not seen that, thanks for sharing; went looking when I saw the ask jump

[adijas]

Was looking at the website last week. So this is brand new. Very nice. Don't know if you have seen this post from me some time ago https://investorshub.advfn.com/boards/read_msg.aspx?message_id=135658044&txt2find=ivro

[db7]

new website up, older version was VERY outdated:

http://invitrointl.com/


also suggest viewing their twitter and facebook pages.. pushing for legislation, industry updates..etc...etc


http://invitrointl.com/a-note-from-the-ceo/

[adijas]

Company had filings out last week. http://www.otcmarkets.com/stock/IVRO/filings

[adijas]

Nice find!

[db7]

could this* be part of their 'targeted social media marketing program"?



*
http://documentslide.com/documents/starting-october-1-this-simple-corrosivity-test-could-save-you-25000-a-day-58a97718accf3.html

[adijas]

yeah, OECD is big.

[db7]

in my prior post, I pointed out this statement, "OECD is currently reviewing the Company’s Ocular IRRITECTION® test method for acceptance as a substitute for animal testing on all future cosmetic products."


Who/what is OECD?
"The Organization for Economic Co-Operation and Development (“OECD”), which is comprised of 35 member countries, Transport Canada, DOT, OSHA, the Consumer Product Safety Commission, the Federal Drug Administration and the International Air Transport Authority "

[adijas]

Info about testing

http://www.mbresearchlabs.com/corrositex/index.htm

http://www.mbresearch.com/in-vitro-toxicology-testing.htm

[db7]

https://www.otcmarkets.com/financialReportViewer?symbol=IVRO&id=171822

think of the implications of that bolded part imo (I made it bold):

"Recent Developments
In late 2014, the Company’s Corrositex™ assay became GHS accepted as a full replacement for animal test results. The Organization for Economic Co-Operation and Development (“OECD”), which is comprised of 35 member countries, Transport Canada, DOT, OSHA, the Consumer Product Safety Commission, the Federal Drug Administration and the International Air Transport Authority have also accepted Corrositex™ as a full replacement test. OECD determined that CORROSITEX™ is the only non-animal corrosivity test which classifies, with 96%+ accuracy, U.N. Packing Groups I, II, III, and noncorrosive as well as their GHS equivalents.
In late 2015, the European Regulatory Program to re-classify all chemicals used in Europe accepted the Company’s CORROSITEX™ test method as a full replacement for animal testing.
OECD is currently reviewing the Company’s Ocular IRRITECTION® test method for acceptance as a substitute for animal testing on all future cosmetic products."




also interesting:
"The Company is also in the process of developing a targeted social media marketing program."

[db7]

http://www.invitrointl.com/currentpress.php

[db7]

IVRO Security Details


Share Structure

Market Value1 $658,619 a/o May 11, 2017
Authorized Shares 40,000,000 a/o May 10, 2017
Outstanding Shares 21,954,809 a/o May 10, 2017
-Restricted 7,616,180 a/o May 10, 2017
-Unrestricted Not Available
Held at DTC Not Available
Float Not Available
Par Value No Par Value


Transfer Agent(s) Verified by Transfer Agent

Pacific Stock Transfer Co.

[db7]

http://www.happi.com/issues/2016-09-02/view_features/proof-positive

[$hellKing]

Maybe they pay a dividend in 2037?

[gabkok]

The company has been having positive performance since 2003. I have been tracking it for a long time. I believe it is a solid value investment.

I hope it gives cash dividend one of these days (soon).

IRAD just delivered a $0.10 special cash dividend into my account this morning.

[Potse]

IVRO(.015)...2015 financials, future looks encouraging....

22M shares outstanding
$330K market cap
$995K revenue
$650K cash (2.9+ cents per share)

I picked up some shares of IVRO today. The fiscal year 2015 financial results press release last week shows nice improvements in the areas of revenue, earnings and cash. It is possible this could represent a significant turning point in the company's history, as the CEO's statements in the press release seem upbeat/encouraging......

INVITRO INTERNATIONAL REPORTS OUTSTANDING FY 2015 FINANCIAL RESULTS, AND CORE TECHNOLOGY REGULATORY PROGRESS

Placentia, CA February 2, 2016 - Today InVitro International (OTC, Pink Sheets, IVRO) reported audited FY 2015 sales of $994,713, up 45% from FY 2014 comparable period. Net income leapt 774% to $232,100 and cash increased 69%

IVRO CEO & President, W. Richard Ulmer, said "The confluence of several positives in our FY 2015 business made this a special year for our company. First, official U.S. Regulatory implementation of the Global Harmonization System (GHS) continued to benefit our Corrositex test technology here and in Europe. Additionally for the first time, Ocular Irritection sales were positively impacted by GHS acceptance in Europe’s REACH program, which over several years will be re-classifying all chemicals used there. Next, our 2014 company relocation along with several new cost saving measures provided important cash growth in 2015. So now looking forward, we believe the pieces will be in place to support promotion of Ocular Irritection should it receive full OECD Regulatory adoption in the near future. Our submission continues to make solid progress in its regulatory review.”

“At InVitro we feel we are moving ever closer to our major goal of corporate sustainability. The 2015 audited financial statements support this feeling and demonstrate the impact of InVitro’s Quasi Reorganization. Because we met the required five consecutive years of profitability, effective October 2014, U.S. Generally Accepted Accounting Principles (GAAP) permitted elimination of accumulated IVRO historical operating losses; thus InVitro achieved a new financial reporting status. As we begin a new year, we remain a dedicated, determined and disciplined team in pursuit of both company and shareholder goals.”

http://www.invitrointl.com/press40.php

[gabkok]

As of 9/30/2010, the company has a book value of $0.0321, and it has been profitable year-over-year for the past six years. Also, its shareholder equity has been growing for the past eight years.

I wonder why its share price has not gone above where it is now.

[gabkok]

As of 9/30/08, the company has a book value of $0.03, and its cash and revenue are growing year over year for the past four or five years.

In addition, it expects revenue for the first Quarter FY 2009 to be best first Quarter since 1996.